Drug intelligence / Profile preview

human umbilical cord blood plasma

Development stage: Phase 2
Administration: Intravenous, Topical

Overview

Human umbilical cord blood plasma is a biological product derived from umbilical cord blood that contains various growth factors, cytokines, and immunomodulatory factors. It has demonstrated regenerative and anti-inflammatory properties in preclinical studies. HUCBP contains significantly lower levels of pro-inflammatory cytokines and higher levels of growth factors compared to adult blood plasma, contributing to its therapeutic potential. Key components include TIMP2 (tissue inhibitor of metalloproteinases 2), which has been shown to promote cognitive function in aged mice.

Other names: HUCBPUCB-PLCBPhUCP

Targets

MMP2 (Matrix metalloproteinase-2)

Beyond the preview

Go deeper on human umbilical cord blood plasma.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on human umbilical cord blood plasma.

Explore the full profile